Evaluating the Fiscal Impact of Antiretroviral Therapy for the Management of HIV in the United States 1987–2023
The analysis illustrates the broader economic benefits to the government attributed to public and private investments to develop and make ART available. The fiscal analysis of investing in ART shows a fourfold gain for the US government. This broader analysis is crucial to help shape health policy and funding decisions.
Authors
- A.T. Paquete (ORCID: https://orcid.org/0000-0001-7162-1400)
- Ryan Thaliffdeen (ORCID: https://orcid.org/0009-0000-7231-1471)
- Mark P. Connolly (ORCID: https://orcid.org/0000-0002-1886-745X)
- Patrick S. Sullivan (ORCID: https://orcid.org/0000-0002-7728-0587)
- Nikolaos Kotsopoulos (ORCID: https://orcid.org/0000-0002-8248-7697)
- Paresh Chaudhari
- James Jarrett (ORCID: https://orcid.org/0000-0002-3570-8581)
- Uche Mordi
Institutions
- NCR (United States) (US)
- University Medical Center Groningen (NL)
- Emory University (US)
- Gilead Sciences (United Kingdom) (GB)
- Gilead Sciences (United States) (US)
- Athens University of Economics and Business (GR)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/ceor.s520050
- Citations
- 5
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 6.98
Funders
- Gilead Sciences
- ViiV Healthcare
- National Institutes of Health
- Centers for Disease Control and Prevention